TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33984151

Group type: EXPERIMENTAL
Intervention: Veliparib and radiotherapy followed by adjuvant veliparib and temozolomide
Number of subjects: 125

Group type: COMPARATOR
Intervention: Concurrent temozolomide and radiotherapy followed by adjuvant temozolomide
Number of subjects: 125
Study: 32124520

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 503

Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 503
Study: 35562720

Group type: EXPERIMENTAL
Intervention: Mild anemia (Hb 10.0-11.0 g/dL)
Number of subjects: 11370

Group type: EXPERIMENTAL
Intervention: Moderate anemia (Hb 7.0-10.0 g/dL)
Number of subjects: 11370

Group type: EXPERIMENTAL
Intervention: Severe anemia (Hb < 7.0 g/dL)
Number of subjects: 11370

Group type: COMPARATOR
Intervention: Mild or moderate anemia
Number of subjects: 11370

Group type: COMPARATOR
Intervention: No anemia
Number of subjects: 11370

Group type: EXPERIMENTAL
Intervention: Anemia severity (mild, moderate, severe)
Number of subjects: 11370
Study: 32268592

Group type: EXPERIMENTAL
Intervention: Taekwondo training (5 times a week for 16 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study: 32860075

Group type: EXPERIMENTAL
Intervention: Anti-PD1 therapy (discontinued due to prolonged remission or unacceptable toxicity)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Machine learning algorithm for predicting progression-free survival (PFS)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Training set performance of machine learning algorithm
Number of subjects: 40
Study: 35013893

Group type: EXPERIMENTAL
Intervention: Atrial ablation (A > V)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Ventricular ablation (V > A)
Number of subjects: 90
Study: 34602470

Group type: EXPERIMENTAL
Intervention: High saturated fat/glycemic index diet (HIGH)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Low saturated fat/glycemic index diet (LOW)
Number of subjects: 49
Study: 32764081

Group type: EXPERIMENTAL
Intervention: Acupuncture (one session of Western medical acupuncture treatment in addition to standard treatment)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Standard treatment according to Norwegian guidelines
Number of subjects: 171
Study: 35703877

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 61
Study: 34500081

Group type: EXPERIMENTAL
Intervention: Milrinone (0.5 ?g/kg/min)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Nitroglycerin (0.2-0.5 ?g/kg/min)
Number of subjects: 52
Study: 36476466

Group type: EXPERIMENTAL
Intervention: Intravenous ketorolac postoperatively and 3 days of oral ketorolac on discharge
Number of subjects: 48

Group type: COMPARATOR
Intervention: Standard-of-care pain protocol involving oxycodone-acetaminophen 5 to 325 on discharge
Number of subjects: 48
Study: 34247414

Group type: EXPERIMENTAL
Intervention: Irritable bowel syndrome (IBS)
Number of subjects: 1322

Group type: EXPERIMENTAL
Intervention: Functional dyspepsia (FD)
Number of subjects: 1322

Group type: COMPARATOR
Intervention: Any sleep disturbance
Number of subjects: 1322
Study: 32599215

Group type: EXPERIMENTAL
Intervention: INSPIRE program (Internet and social media-based intervention)
Number of subjects: 2578
Study: 34895160

Group type: EXPERIMENTAL
Intervention: High dose citrate (4.5 mmol/L)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Low dose citrate (2.5 mmol/L)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Both groups (high and low citrate)
Number of subjects: 35
Study: 33119572

Group type: EXPERIMENTAL
Intervention: mHealth intervention (OL@‐OR@ smartphone app)
Number of subjects: 726

Group type: COMPARATOR
Intervention: Control version of the intervention
Number of subjects: 726
Study: 35197332

Group type: EXPERIMENTAL
Intervention: Interactive group setting intervention divided into five sessions (self-care as a leader, leadership attitudes and behaviour, motives, needs and stressors of employees, strengthen the resource 'team', reflection and focus groups)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Interactive group setting intervention
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Focus group discussions
Number of subjects: 93
Study: 34053801

Group type: COMPARATOR
Intervention: 2% lidocaine with epinephrine 1:100,000
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: 4% articaine with epinephrine 1:100,000
Number of subjects: 139
Study: 32409981

Group type: EXPERIMENTAL
Intervention: 50 mg IV tramadol
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4 mg IV morphine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34694261

Group type: EXPERIMENTAL
Intervention: Dihydropyridine calcium channel blockers (CCB)
Number of subjects: 5020

Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 5020
Study: 32074324

Group type: EXPERIMENTAL
Intervention: Mentored group (RTM)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Nonmentored group
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study: 34982007

Group type: EXPERIMENTAL
Intervention: Multispot technique (20 ms exposure time)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-spot technique (150 ms exposure time)
Number of subjects: 0
Study: 34001407

Group type: EXPERIMENTAL
Intervention: Cryotherapy (80 minutes applied in addition to standard oral care)
Number of subjects: 32
Study: 33072188

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (20 grams total, with a 15-minute loading dose followed by a 24-hour maintenance infusion)
Number of subjects: 1126

Group type: COMPARATOR
Intervention: Placebo (administered in the same manner as magnesium sulfate)
Number of subjects: 1126
Study: 33657760

Group type: EXPERIMENTAL
Intervention: Continuous intra‐articular (IA) infusion analgesia
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block (FNB)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Continuous epidural analgesia (EA)
Number of subjects: 72
Study: 631335334

Group type: EXPERIMENTAL
Intervention: Endovascular treatment (EVT)
Number of subjects: 726

Group type: COMPARATOR
Intervention: Medical treatment (control group)
Number of subjects: 726
Study: 34213086

Group type: EXPERIMENTAL
Intervention: Yoga intervention for 8 weeks (n=21)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Wait-list control for 8 weeks (n=20)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Baseline Treatment Expectancy Scale (TES)
Number of subjects: 41
Study: 34000325

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg.kg‐1
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fentanyl 2 μg.kg‐1
Number of subjects: 100
Study: 35174670

Group type: EXPERIMENTAL
Intervention: Telerehabilitation exercise program via Zoom, 3 times a week for 12 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (no telerehabilitation)
Number of subjects: 28
Study: 33743321

Group type: EXPERIMENTAL
Intervention: Risk evaluation score for vitamin D insufficiency
Number of subjects: 2280

Group type: EXPERIMENTAL
Intervention: Risk evaluation score for vitamin D deficiency
Number of subjects: 2280

Group type: EXPERIMENTAL
Intervention: Optimal points of change for risk scores
Number of subjects: 2280
Study: 33957103

Group type: EXPERIMENTAL
Intervention: Team-based care plus clinical decision support system (CDSS)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Team-based care alone
Number of subjects: 38
Study: 33261915

Group type: EXPERIMENTAL
Intervention: Immediate nicotine reduction condition (0.4 mg/g nicotine cigarettes)
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: Gradual nicotine reduction condition (15.5 to 0.4 mg/g)
Number of subjects: 957

Group type: COMPARATOR
Intervention: Control condition (15.5 mg/g)
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: Overall participants
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: Participants interested in quitting
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: Participants with greater dependence scores
Number of subjects: 957

Group type: EXPERIMENTAL
Intervention: Participants aged 18–24
Number of subjects: 957
Study: 33933731

Group type: EXPERIMENTAL
Intervention: Dietary weight loss intervention for 8 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Habitual diet (control group)
Number of subjects: 52
Study: 34214095

Group type: EXPERIMENTAL
Intervention: Rotasiil (3 doses)
Number of subjects: 3508

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3508
Study: 36069871

Group type: EXPERIMENTAL
Intervention: Litifilimab 450 mg
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 32019434

Group type: EXPERIMENTAL
Intervention: Cocoa beverage
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cocoa and UBF beverage
Number of subjects: 60
Study: 32589851

Group type: EXPERIMENTAL
Intervention: MiYoga (n=21)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Waitlist control (n=21)
Number of subjects: 42
Study: 35075494

Group type: EXPERIMENTAL
Intervention: Ningmitai capsule (1.52 g, three times daily)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102
Study: 34325077

Group type: EXPERIMENTAL
Intervention: R-PDT: PDT with riboflavin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cu-PDT: PDT with curcumin
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG: laser application
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group: resin-modified glass ionomer restoration with no treatment
Number of subjects: 80
Study: 35694924

Group type: EXPERIMENTAL
Intervention: Olfactory training (frequent short-term sniffing various odors) for 4 months, performed twice a day
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo group (not specified)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Olfactory training
Number of subjects: 37
Study: 32487881

Group type: EXPERIMENTAL
Intervention: Patient rankings of adverse events (AEs) and adverse symptoms (ASs) severity
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physician rankings of adverse events (AEs) and adverse symptoms (ASs) severity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Decision-making and quality-of-life outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient perspective on AEs/ASs
Number of subjects: 0
Study: 32272284

Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Omalizumab 150 mg stepped up to 300 mg
Number of subjects: 314

Group type: COMPARATOR
Intervention: Omalizumab 150 mg
Number of subjects: 314
Study: 35694107

Group type: EXPERIMENTAL
Intervention: FES+MT training (Functional Electrical Stimulation combined with Mirror Therapy)
Number of subjects: 10

Group type: COMPARATOR
Intervention: MT training (Mirror Therapy)
Number of subjects: 10
Study: 33938678

Group type: EXPERIMENTAL
Intervention: e‐pQLB (0.375% ropivacaine + 100 mcg epinephrine, 20 mL each side)
Number of subjects: 52

Group type: COMPARATOR
Intervention: pQLB (0.375% ropivacaine alone, 20 mL each side)
Number of subjects: 52
Study: 33378772

Group type: EXPERIMENTAL
Intervention: Fluorescence imaging with indocyanine green (ICG)
Number of subjects: 7

Group type: COMPARATOR
Intervention: White light alone
Number of subjects: 7
Study: 35574691

Group type: EXPERIMENTAL
Intervention: TQC3564 single ascending dose (SAD) 25 to 1200 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TQC3564 multiple ascending dose (MAD) 100 or 500 mg, QD
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TQC3564 food-effect study 300 mg
Number of subjects: 0
Study: 34174090

Group type: EXPERIMENTAL
Intervention: Reboxetine (4 mg) plus hyoscine butylbromide (20 mg)
Number of subjects: 12
Study: 32048107

Group type: EXPERIMENTAL
Intervention: bezlotoxumab 10 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35026861

Group type: EXPERIMENTAL
Intervention: Brinzolamide
Number of subjects: 125

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 125
Study: 33928916

Group type: EXPERIMENTAL
Intervention: KCONVAC 5 μg/dose
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: KCONVAC 10 μg/dose
Number of subjects: 560

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: KCONVAC 5 μg/dose (0/14 regimen)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: KCONVAC 10 μg/dose (0/14 regimen)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Placebo (0/14 regimen)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: KCONVAC 5 μg/dose (0/28 regimen)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: KCONVAC 10 μg/dose (0/28 regimen)
Number of subjects: 560

Group type: COMPARATOR
Intervention: Placebo (0/28 regimen)
Number of subjects: 560

Group type: EXPERIMENTAL
Intervention: KCONVAC (both regimens)
Number of subjects: 560
Study: 35217898

Group type: EXPERIMENTAL
Intervention: 20 Hz stimulation
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 40 Hz stimulation
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 60 Hz stimulation
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 80 Hz stimulation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 19
Study: 34666273

Group type: EXPERIMENTAL
Intervention: bilateral STN-DBS plus optimal drug therapy (ODT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: optimal drug therapy (ODT) alone
Number of subjects: 30
Study: 36296994

Group type: EXPERIMENTAL
Intervention: 24 g of fiber/day from 2 buns of 12 g each
Number of subjects: 28

Group type: COMPARATOR
Intervention: 12 g of fiber/day from 2 buns of 6 g each
Number of subjects: 28
Study: 34371825

Group type: EXPERIMENTAL
Intervention: Culinary education through 12 weekly 30-min one-on-one telemedicine culinary coaching sessions
Number of subjects: 28
Study: 33153517

Group type: EXPERIMENTAL
Intervention: CRP point-of-care testing in intervention practices
Number of subjects: 47000

Group type: COMPARATOR
Intervention: Usual practice in control practices
Number of subjects: 47000
Study: 35685601

Group type: EXPERIMENTAL
Intervention: 1 ICU visit prior to patient's admission
Number of subjects: 38

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 38
Study: 34116166

Group type: COMPARATOR
Intervention: Adopted infants (n = 34)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Infants reared by biological mothers (n = 113)
Number of subjects: 147
Study: 34774746

Group type: EXPERIMENTAL
Intervention: CPO–RAP
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: CPO
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: CPO–RAP (RAP > 8 mm Hg)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: CPO–RAP (RAP ≤ 8 mm Hg)
Number of subjects: 157
Study: 33709941

Group type: EXPERIMENTAL
Intervention: Interactive web‐based sexual health literacy intervention
Number of subjects: 781

Group type: COMPARATOR
Intervention: Single webpage of online information about condom use
Number of subjects: 781
Study: 35488875

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Fibrin (PRF)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 50
Study: 32919526

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg intravenously every 3 weeks for up to 35 cycles
Number of subjects: 1073
Study: 35180920

Group type: EXPERIMENTAL
Intervention: Intravascular interventional embolization (group A)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Craniotomy clipping (group B)
Number of subjects: 102
Study: 34936266

Group type: EXPERIMENTAL
Intervention: Tongtuo Fu's acupuncture
Number of subjects: 150

Group type: COMPARATOR
Intervention: Tongtuo acupuncture
Number of subjects: 150

Group type: COMPARATOR
Intervention: Conventional Fu's acupuncture
Number of subjects: 150
Study: 35216556

Group type: EXPERIMENTAL
Intervention: recombinant human GH (rhGH)
Number of subjects: 44
Study: 34128386

Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (tDCS) for 30 minutes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation for 30 minutes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Active transcranial direct current stimulation (tDCS)
Number of subjects: 0
Study: 33129989

Group type: EXPERIMENTAL
Intervention: Vadadustat
Number of subjects: 3476

Group type: COMPARATOR
Intervention: Darbepoetin alfa
Number of subjects: 3476

Group type: EXPERIMENTAL
Intervention: Vadadustat and Darbepoetin alfa (pooled)
Number of subjects: 3476
Study: 35487229

Group type: EXPERIMENTAL
Intervention: Safer gambling message condition (experiment 1)
Number of subjects: 1509

Group type: COMPARATOR
Intervention: Control condition (experiment 1)
Number of subjects: 1509

Group type: EXPERIMENTAL
Intervention: Yellow version of gambling message (experiment 2)
Number of subjects: 1509

Group type: COMPARATOR
Intervention: Control condition (experiment 2)
Number of subjects: 1509

Group type: EXPERIMENTAL
Intervention: Black-and-white gambling message condition (experiment 2)
Number of subjects: 1509

Group type: EXPERIMENTAL
Intervention: Gambling message condition (experiment 3)
Number of subjects: 1509

Group type: COMPARATOR
Intervention: Control condition (experiment 3)
Number of subjects: 1509
Study: 34784891

Group type: EXPERIMENTAL
Intervention: Interactive computer-based decision aid (DA)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Usual counselling by family doctor (CG)
Number of subjects: 130
Study: 35385794

Group type: EXPERIMENTAL
Intervention: Mebendazole 500 mg orally BID for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 40
Study: 34606989

Group type: EXPERIMENTAL
Intervention: multiple self‐collection test kits
Number of subjects: 1048

Group type: COMPARATOR
Intervention: multiple referrals for standard clinic‐based tests
Number of subjects: 1048
Study: 32673356

Group type: EXPERIMENTAL
Intervention: 80 kVp, 320 mgl/ml CM at 4 ml/s (Group B)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 80 kVp, 320 mgl/ml CM at 5 ml/s (Group C)
Number of subjects: 93

Group type: COMPARATOR
Intervention: 100 kVp, 400 mgl/ml CM at 4 ml/s (Group A)
Number of subjects: 93
Study: 35981780

Group type: EXPERIMENTAL
Intervention: Participation in all 3 FU data collection rounds
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Participation in FU rounds
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Physical examination and cardiac assessment participation
Number of subjects: 67
Study: 33774741

Group type: EXPERIMENTAL
Intervention: AMOR (Acceptance, Mindfulness, Optimism, Resilience) Method parent group
Number of subjects: 35
Study: 33321523

Group type: EXPERIMENTAL
Intervention: 8-week exercise training
Number of subjects: 14
Study: 33338971

Group type: EXPERIMENTAL
Intervention: alprazolam (1.5 mg daily for 5 days)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: etifoxine (150 mg daily for 5 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 35020462

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine Transdermal System (d-ATS) 5 mg patch applied for 9 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine Transdermal System (d-ATS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34706706

Group type: EXPERIMENTAL
Intervention: Spinal manipulative therapy and home stretching exercises
Number of subjects: 131

Group type: COMPARATOR
Intervention: Home stretching exercises alone
Number of subjects: 131
Study: 32048379

Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure (CPAP) treatment for 6 months
Number of subjects: 116

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 116
Study: 35357316

Group type: EXPERIMENTAL
Intervention: Web-based application for lifestyle advice and self-control of risk factors, accessed for 25 weeks.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care (cardiac rehabilitation only).
Number of subjects: 150
Study: 33095213

Group type: EXPERIMENTAL
Intervention: Supramolecular ligand from the drug-candidate library
Number of subjects: 0
Study: 32868356

Group type: EXPERIMENTAL
Intervention: Pharmacy intervention pathway - rapid point-of-care HCV PCR test and direct-acting antivirals (DAAs) delivered via pharmacist.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Education-only pathway - counseling on HCV and referral to nurse-led clinic or general practitioner for HCV testing.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pharmacy intervention pathway
Number of subjects: 0

Group type: COMPARATOR
Intervention: Education-only pathway
Number of subjects: 0
Study: 35840351

Group type: EXPERIMENTAL
Intervention: Adrenomedullin (10 ng/kg/min)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Adrenomedullin (15 ng/kg/min)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 33978823

Group type: EXPERIMENTAL
Intervention: Glasdegib plus low-dose cytarabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 35233974

Group type: EXPERIMENTAL
Intervention: Escitalopram/memantine (ESC/MEM)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Escitalopram/placebo (ESC/PBO)
Number of subjects: 26
Study: 36002761

Group type: EXPERIMENTAL
Intervention: Sublingual dexmedetomidine 180-µg
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Sublingual dexmedetomidine 120-µg
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Sublingual dexmedetomidine (all doses pooled)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 506
Study: 33369195

Group type: EXPERIMENTAL
Intervention: PRADO-IC transition programme (administrative assistance and nurse follow-up for 2 to 6 months)
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Cost to avoid a readmission for heart failure within 1 year
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Clinical care pathways
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: System economic outcomes
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Perceived problems and benefits of the PRADO-IC
Number of subjects: 404
Study: 34215599

Group type: EXPERIMENTAL
Intervention: LDL-C ≥1.8 mmol/L
Number of subjects: 551

Group type: COMPARATOR
Intervention: LDL-C <1.8 mmol/L
Number of subjects: 551
Study: 36205471

Group type: EXPERIMENTAL
Intervention: Provider discussion of genetic counseling (GC)
Number of subjects: 52